Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment

The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonaguro, Luigi, Buonaguro, Franco M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215134/
https://www.ncbi.nlm.nih.gov/pubmed/32419838
http://dx.doi.org/10.1186/s13027-020-00302-x
_version_ 1783532115547127808
author Buonaguro, Luigi
Buonaguro, Franco M.
author_facet Buonaguro, Luigi
Buonaguro, Franco M.
author_sort Buonaguro, Luigi
collection PubMed
description The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency. Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19.
format Online
Article
Text
id pubmed-7215134
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72151342020-05-12 Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment Buonaguro, Luigi Buonaguro, Franco M. Infect Agent Cancer Short Report The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency. Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19. BioMed Central 2020-05-12 /pmc/articles/PMC7215134/ /pubmed/32419838 http://dx.doi.org/10.1186/s13027-020-00302-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Buonaguro, Luigi
Buonaguro, Franco M.
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
title Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
title_full Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
title_fullStr Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
title_full_unstemmed Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
title_short Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
title_sort knowledge-based repositioning of the anti-hcv direct antiviral agent sofosbuvir as sars-cov-2 treatment
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215134/
https://www.ncbi.nlm.nih.gov/pubmed/32419838
http://dx.doi.org/10.1186/s13027-020-00302-x
work_keys_str_mv AT buonaguroluigi knowledgebasedrepositioningoftheantihcvdirectantiviralagentsofosbuvirassarscov2treatment
AT buonagurofrancom knowledgebasedrepositioningoftheantihcvdirectantiviralagentsofosbuvirassarscov2treatment

Ejemplares similares